Fremanezumab for the preventive treatment of migraine in adults
- 26 June 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 12 (8) , 741-748
Abstract
Introduction: The Calcitonin Gene-Related Peptide (CGRP) has been implicated in migraine pathophysiology due to its role in neurogenic inflammation and transmission of trigeminovascular nociceptive signal. New molecules targeting CGRP and its receptor have been developed as migraine-specific preventative treatments. Fremanezumab (or TEV-48125, LBR-101), a human monoclonal antibody against CGRP, has been recently approved for clinical use by FDA and EMA. Areas covered: This paper briefly discusses the calcitonin family of neurotransmitters and resultant activation pathways, and in depth the chemical properties, pharmacodynamics, pharmacokinetics, clinical efficacy and safety of Fremanezumab for the prophylactic treatment of migraine. Expert opinion: Fremanezumab, a migraine-specific drug, iseffective and safe as a prophylactic treatment of chronic and episodic migraine. As a monoclonal antibody, it was not associated to liver toxicity and is not expected to interact with other drugs. The long half-life might improve patients’ compliance. Long-term effects of CGRP block in cardiovascular, grastrointestinal and bone functions should be evaluated in ongoing trials, since CGRP is involved inmultiple biological activities in the human body. Nevertheless, targeting CGRP itself allows the receptor binding with other ligands involved in several physiological functions. Thus, the long-term treatment with Fremanezumab is expected to be associated with a lower risk of severe adverse effects.Keywords
This publication has 71 references indexed in Scilit:
- CGRP/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization?Trends in Pharmacological Sciences, 2019
- Migraine is first cause of disability in under 50s: will health politicians now take notice?The Journal of Headache and Pain, 2018
- The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migrainePain, 2017
- Calcitonin gene-related peptide and pain: a systematic reviewThe Journal of Headache and Pain, 2017
- Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative DiseasesMediators of Inflammation, 2017
- Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in ratMolecular and Cellular Neuroscience, 2011
- CGRP and its receptors provide new insights into migraine pathophysiologyNature Reviews Neurology, 2010
- Neurobiology in primary headachesBrain Research Reviews, 2005
- Migraine — Current Understanding and TreatmentNew England Journal of Medicine, 2002
- Alternative production of calcitonin and CGRP mRNA is regulated at the calcitonin-specific splice acceptorNature, 1989